The risk of venous thromboembolism (VTE), or blood clots, in individuals with sickle cell trait (SCT) is higher than in individuals without the trait. However, the risk is lower than for those with ...

This condition can manifest as a result of various underlying issues, including homozygous alpha thalassemia, a severe fetal ...

The risk of venous thromboembolism (VTE), or blood clots, in individuals with sickle cell trait (SCT) is higher than in ...

In one study, men with priapism related to sickle cell disease found that exercise alone or in combination with warm or cold ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

Agios Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) ...

Mitapivat, the company’s lead PK activator, was previously granted FDA orphan drug designation for the treatment of PK deficiency, thalassemia, and sickle cell disease. Tebapivat is not approved for ...

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined around 1.2% in the past three months, losing almost $3 ...

Intelligent Alpha founder and CEO Doug Clinton joins the show to break ... a cell therapy treatment for sickle cell disease and beta-thalassemia. Seigerman notes that the uptake has been slow as it ...

Intelligent Alpha founder and CEO Doug Clinton joins the show to break ... a cell therapy treatment for sickle cell disease and beta-thalassemia. Seigerman notes that the uptake has been slow as it ...